<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Our Pipeline

Building drug conjugates with multimodal mechanisms of action that provide an impenetrable wall of activity.

Progression towards the clinic by 2026 with a strategy for rapid FIH data acquisition

Programs

Discovery

Preclinical

IND-Enabling

Preclinical

CO-1024:
Solid Tumor

CO-1008:
Hematologic Tumor

Therapeutic Discovery

CO-1025:
Solid & Hematologic Tumor

CO-1002:
Solid & Hematologic Tumor

Therapeutic Discovery


Various
Solid & Hematologic Tumor

Target Validation

Our Therapeutic Programs

CO-1024: 1st in Class of ADCs to Treat Solid Tumors

Despite considerable progress made in the treatment of Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Gastric Cancer, and Pancreatic Cancers with immune therapy, only a fraction of these patients respond with durable responses. CO-1024-directed ADCs offer a new approach to the treatment of these malignancies with a high unmet medical need.
 
ADCs against CO-1024 Target A target with an elevated and homogenous expression with a biological role in tumor growth and survival.
CO-1024_2
CO-1024_3
CO-1024_5
CO-1024_6

A Franchise of CO-1008 Directed Therapies

 
Patients with Acute Myeloid Leukemia (AML) currently have few therapeutic options that provide a durable response to tumors. Despite considerable progress in treatment for Non-Hodgkins Lymphoma (NHL), a significant population of Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), and B Cell Acute Lymphoblastic Leukemia (B-ALL) tumors are either CD19-negative or relapse as CD19-negative tumors. CO-1008 Antibody Drug Conjugate (ADC) aims to resolve the unmet medical needs of patients diagnosed with Acute Myeloid Leukemia (AML), specifically in tumors with MLL/KMT2A fusions.  CO-1008 target expression is driven by MLL/KMT2A fusion products and regulates the hyperinflammatory nature of these tumors.  The CO-1008 target has low toxicity liabilities with expression absent in hematopoietic stem cells and common myeloid progenitors. 
 
2
4-3
5-1
6-3
Antibody-based therapies against CO-1008 a target with a profile that offers an improved therapeutic index